FY2025 · ended Dec 31, 2025 · Revenue $43.77M, +589.9% YoY · Filed Mar 23, 2026
Xilio Therapeutics, Inc. (XLO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $43.8 million and a net loss of $35.0 million. Free cash flow was -$5.5 million. As of Jun 30, 2026 it held $136.0 million in cash and investments and $6.3 million in total debt.
Revenue (TTM)
$64.09M
+327.3% vs year-ago TTM
Net income (TTM)
$-21.83M
+61.2% vs year-ago TTM
Operating cash flow (TTM)
$-60.60M
-354.7% vs year-ago TTM
Free cash flow (TTM)
$-61.27M
-345.1% vs year-ago TTM
EPS
$-4.19
+72.5% vs prior year
Dividend per share
None
Shares outstanding
5.78M
-88.8% vs prior year
Net cash
$129.74M
as of Jun 30, 2026
Operating margin
-48.9%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XLO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1840233
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $43.8M | $6.3M | — | — | — |
| Operating income | -$42.0M | -$60.6M | -$79.1M | -$89.1M | -$75.0M |
| Net income | -$35.0M | -$58.2M | -$76.4M | -$88.2M | -$75.8M |
| Diluted EPS | -$4.19 | -$15.24 | -$2.78 | -$3.22 | -$13.52 |
| Operating cash flow | -$5.0M | -$18.4M | -$68.6M | -$75.7M | -$80.8M |
| Free cash flow | -$5.5M | -$18.4M | -$69.1M | -$77.6M | -$81.9M |
| Total assets | $154.7M | $71.1M | $60.9M | $139.2M | $218.1M |
| Total liabilities | $119.4M | $53.5M | $24.1M | $33.5M | $32.6M |
| Stockholders' equity | $35.3M | $17.6M | $36.8M | $105.6M | $185.4M |
| Cash and investments | $137.5M | $55.3M | $44.7M | $120.4M | $198.1M |
| Total debt | $7.0M | $8.1M | $9.2M | $10.2M | $11.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 12, 2026 | Jun 10, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
| ARS | Annual report to shareholders | Apr 28, 2026 | Dec 31, 2025 |
All 357 Xilio Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.